IBA Reports Half Year Results for 2018
To read the full 2018 half year results press release with the operating review, please open the pdf document on teh following link
Louvain-La-Neuve, Belgium, August 23, 2018 - IBA (Ion Beam Applications SA, EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated results for the first half of 2018.
| H1 2018 |
| H1 2017 |
| Variance |
| Variance |
|Sales & services||114 675||151 613||-36 938||-24.4%|
|REBITDA||-706||5 264||-5 970||-113.4%|
|% of sales||-0.6%||3.5%|
|REBIT||-4 533||1 901||-6 434||-338.6%|
|% of sales||-4%||1.3%|
|Net result||-7 015||-4 655||-2 360||N/A|
|% of sales||-6.1%||-3.1%|
Olivier Legrain, Chief Executive Officer of IBA SA commented: "IBA made good progress in the first six months of the year with five new proton therapy sales and a record 11 Other Accelerators sales. As expected, revenue recognition was slower over the first half, due to the phasing of backlog conversion and only one new Proton Therapy contract delivering revenues. Reacting to this environment, the Group maintained tight cost controls, making almost EUR 10 million of savings in the first half, whilst maintaining market dominance with all five proton therapy projects sold in the first six months of 2018 awarded to IBA. The Group continued to convert its almost EUR 1 billion backlog in Proton Therapy and Other Accelerators equipment and services with 20 projects on track.
"Looking to the second half of the year, IBA reiterates its outlook for 2018 of a positive REBIT and net profit after tax, driven by a second half weighting, which includes recently signed projects awaiting financing, a strong pipeline of near-term projects and five installations due to start in the second half. We remain confident in the long-term prospects for proton therapy and our focus remains to grow the market through clear evidence generation and improving affordability, whilst maintaining a superior, technologically advanced offering. Most notably, the recent collaboration with Elekta, now formally signed, will complement the Group's existing partnerships with Raysearch and Philips and see the Group enhancing its technological lead of the market in the important area of software as well as benefitting from co-marketing synergies."
A conference call to discuss the half year results will be held today at 3pm CEST / 2pm BST / 9am EDT / 6am PDT and can be accessed online at: http://arkadinemea-events.adobeconnect.com/iba2308/event/registration.html
If you would like to participate in the Q&A, please dial (PIN code 20839073#):
Belgium: +32 2 403 58 16
UK: +44 20 71 94 37 59
NL: +31 207 09 51 19
LU: +352 2 730 01 63
US: +1 64 67 22 49 16
FR: +33 1 72 72 74 03
The presentation will be available on IBA's investor relations website and on https://iba-worldwide.com/content/half-year-2018-results-web-conference-details-and-presentation shortly before the call.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
Third Quarter Business Update November 15, 2018
Full Year Results 2018 March 21, 2019
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
*Proteus®ONE and Proteus®PLUS are brand names of Proteus 235
For further information, please contact:
Chief Financial Officer
+32 10 475 890
Vice-President Corporate Communication
+32 10 475 890
For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Matthew Neal, Olivia Manser
+44 (0) 20 3709 5700